Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Share-based Compensation (2020 - 2026)

Cytek Biosciences filings provide 6 years of Share-based Compensation readings, the most recent being $5.5 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 21.08% to $5.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.6 million, a 8.43% decrease, with the full-year FY2025 number at $24.6 million, down 8.43% from a year prior.
  • Share-based Compensation hit $5.5 million in Q4 2025 for Cytek Biosciences, down from $5.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.2 million in Q2 2024 to a low of $456000.0 in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $5.6 million (2025), compared with a mean of $4.9 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 1848.41% in 2021 and later decreased 21.08% in 2025.
  • Cytek Biosciences' Share-based Compensation stood at $3.0 million in 2021, then soared by 48.44% to $4.5 million in 2022, then grew by 26.97% to $5.7 million in 2023, then increased by 23.53% to $7.0 million in 2024, then decreased by 21.08% to $5.5 million in 2025.
  • The last three reported values for Share-based Compensation were $5.5 million (Q4 2025), $5.6 million (Q3 2025), and $6.8 million (Q2 2025) per Business Quant data.